California Institute for Regenerative Medicine

Plasticell appoints Dr. Aaron T. T. Chuang as chief scientific officer

Monday, June 15, 2015

Plasticell, a regenerative medicine company utilizing combinatorial technologies for stem cell research and in developing cell therapies, has recruited Dr. Aaron Chuang to its executive management team in the role of chief scientific officer. Previously, Chuang was research director at the regenerative medicine unit of GlaxoSmithKline, where he worked for over 18 years. As Plasticell’s chief scientific officer, Chuang takes on responsibility for preclinical therapeutic programmes, scientific oversight of collaborations and alliances, as well as external scientific communications. 

[Read More]

Asterias Biotherapeutics initiates trial for complete cervical spinal cord injury

Thursday, March 5, 2015

Asterias Biotherapeutics, a biotechnology company in the emerging field of regenerative medicine, announced that Atlanta-based Shepherd Center, a rehabilitation hospital for spinal cord injury and brain injury, has commenced enrollment for the phase I/IIa clinical trial of AST-OPC1 (oligodendrocyte progenitor cells) in newly injured patients with sensory and motor complete cervical spinal cord injury (SCI).

[Read More]